Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Recombinant MAGE-3.1 Antigen

Known as: MAGE-3, MAGE-3.1, MAGEA3 
A recombinant tumor-specific melanoma antigen. Vaccination with recombinant MAGE-3.1 antigen may induce a host immune response against MAGE… Expand
National Institutes of Health

Related topics

Related topics

4 relations
MAGEA3 geneMAGEA3 protein, humanMAGEA3 wt AlleleNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
BackgroundUnderstanding the interactions between tumor and the host immune system is critical to finding prognostic biomarkers… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The abscopal effect associated with a systemic anti-melanoma immune response.
The clearance of nonirradiated tumors after localized radiation therapy is known as the abscopal effect. Activation of an… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Purpose: Tumor antigen–specific monoclonal antibodies (mAb) block oncogenic signaling and induce Fcγ receptor (FcγR)–mediated… Expand
  • figure 2
  • figure 2
  • figure 3
  • figure 4
  • figure 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Immunization to multiple defined tumor antigens for specific immune therapy of human cancer has thus far proven difficult… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
Vaccination with dendritic cells (DCs) pulsed with tumor antigen peptides has shown promise in the treatment of melanoma… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Phase I study in melanoma patients of a vaccine with peptide‐pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that can be used for vaccination purposes, to induce a… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Expression of MAGE‐antigens in normal tissues and cancer
The human MAGE gene family encodes products that can be recognized by autologous cytotoxic T cells. Because MAGE genes are silent… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11
In this study we used TEPITOPE, a new epitope prediction software, to identify sequence segments on the MAGE-3 protein with… Expand
  • figure 1
  • table I
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
Human melanoma cell line MZ2-MEL expresses several antigens recognized by autologous cytolytic T lymphocyte (CTL) clones. We… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
1994
Highly Cited
1994
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
The human MAGE-3 gene is expressed in many tumors of several histological types but it is silent in normal tissues, with the… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE